Shinpoong Pharmaceutical Co Ltd
Shinpoong Pharmaceutical Co.,Ltd, together with its subsidiaries, manufactures and sells pharmaceutical products in South Korea. The company offers cephalosporin antibiotics; penicillin antibiotics; and finished products, as well as antivirals, anticancer drugs, painkillers, anti-inflammatory products, and anthelmintics. It provides active pharmaceutical ingredients; Pyramax, an anti-malarial dru… Read more
Shinpoong Pharmaceutical Co Ltd (019175) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.034x
Based on the latest financial reports, Shinpoong Pharmaceutical Co Ltd (019175) has a cash flow conversion efficiency ratio of 0.034x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩8.94 Billion) by net assets (₩264.20 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Shinpoong Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Shinpoong Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Shinpoong Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shinpoong Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Apollo Micro Systems Limited
NSE:APOLLO
|
1.232x |
|
Boss Energy Ltd
AU:BOE
|
0.077x |
|
Ridley Corporation Limited
PINK:RIDYF
|
0.068x |
|
Prime Medicine, Inc. Common Stock
NASDAQ:PRME
|
-0.217x |
|
Bukit Uluwatu Villa Tbk
JK:BUVA
|
0.023x |
|
BRBI BR Partners S.A. ADSs
NASDAQ:BRBI
|
0.136x |
|
Ningbo Ligong Online Monitoring Technology Co Ltd
SHE:002322
|
0.035x |
|
EirGenix
TWO:6589
|
-0.020x |
Annual Cash Flow Conversion Efficiency for Shinpoong Pharmaceutical Co Ltd (2014–2024)
The table below shows the annual cash flow conversion efficiency of Shinpoong Pharmaceutical Co Ltd from 2014 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩258.09 Billion | ₩-15.15 Billion | -0.059x | +35.91% |
| 2023-12-31 | ₩270.78 Billion | ₩-24.81 Billion | -0.092x | -14.59% |
| 2022-12-31 | ₩330.76 Billion | ₩-26.44 Billion | -0.080x | +60.09% |
| 2021-12-31 | ₩354.56 Billion | ₩-71.03 Billion | -0.200x | -473.78% |
| 2020-12-31 | ₩374.33 Billion | ₩20.06 Billion | 0.054x | -42.08% |
| 2019-12-31 | ₩209.13 Billion | ₩19.35 Billion | 0.093x | -40.11% |
| 2018-12-31 | ₩207.48 Billion | ₩32.05 Billion | 0.154x | +219.87% |
| 2017-12-31 | ₩210.11 Billion | ₩10.15 Billion | 0.048x | -44.76% |
| 2016-12-31 | ₩216.85 Billion | ₩18.96 Billion | 0.087x | +72.25% |
| 2015-12-31 | ₩194.86 Billion | ₩9.89 Billion | 0.051x | +20285.41% |
| 2014-12-31 | ₩191.51 Billion | ₩-48.16 Million | 0.000x | -- |